Latest Amylyx Pharmaceuticals News & Updates

See the latest news and media coverage for Amylyx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amylyx Pharmaceuticals (Amylyx)

Biopharmaceutical company developing novel therapies

amylyx.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 150–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Amylyx Pharmaceuticals (Amylyx)

In short: Amylyx Pharmaceuticals advanced its rare disease pipeline and resolved major litigation while transitioning its lead programs in 2025-2026.

Company announcements

June 23 Amylyx

Amylyx to present Phase 1 AMX0114 data at ENCALS 2026

The LUMINA trial showed no drug-related serious adverse events in Cohort 1, supporting further study.

May 15 Amylyx

Amylyx publishes positive HELIOS trial results in Wolfram syndrome

Week 24 and 48 results show improved pancreatic function and visual acuity stabilization, with favorable safety.

May 7 Amylyx

Amylyx reports Q1 2026 financial results

R&D expenses rise to $27.6M, net loss $41.3M. LUCIDITY trial enrollment complete, topline data expected Q3 2026. Cash runway into 2028.

May 5 Amylyx

Amylyx announces U.S. Expanded Access Program for avexitide

The program provides access to eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Avexitide is in Phase 3 LUCIDITY trial with data expected Q3 2026.

Media coverage

July 16 STAT

Amylyx nears pivotal endocrine drug study readout

Amylyx will read out results for a rare endocrine disorder treatment, a pivotal moment.

July 10 Stockhouse

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx&CloseCurlyDoubleQuote; or the “Company&CloseCurlyDoubleQuote;) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock...

July 3 AOL

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties...

July 1 STAT

The biotech scorecard for the third quarter: 15 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.

Never miss news about Amylyx

Track Amylyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Amylyx competitors & trending companies

Browse news for competitors to Amylyx and other trending companies.